Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

Explore clinical trials studying Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer trial results

Recruiting

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071

Conditions: Advanced Solid Tumors Harboring the KRAS G12C Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +18 more
Locations: Novartis Investigative Site Sint-Niklaas, Oost Vlaanderen, Belgium

Novartis Investigative Site Montreal, Quebec, Canada

Novartis Investigative Site Guangzhou, Guangdong, China

Novartis Investigative Site Kashiwa, Chiba, Japan

View Trial Details

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer trial results

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Related conditions